<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02503423</url>
  </required_header>
  <id_info>
    <org_study_id>ASTX660-01</org_study_id>
    <nct_id>NCT02503423</nct_id>
  </id_info>
  <brief_title>Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas</brief_title>
  <official_title>Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astex Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astex Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, dose-escalation Phase 1/2 study to assess the safety of ASTX660,&#xD;
      determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), and recommended&#xD;
      dosing regimen, and to obtain preliminary efficacy, pharmacokinetic (PK), and target&#xD;
      engagement data, in subjects with advanced solid tumors or lymphoma for whom standard&#xD;
      life-prolonging measures are not available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASTX660 is a synthetic small molecule dual antagonist of cellular inhibitor of apoptosis&#xD;
      protein (cIAP) 1 and X-linked inhibitor of apoptosis protein (XIAP) that has been shown to&#xD;
      have potent proapoptotic and tumor growth inhibitory activity in nonclinical models. The&#xD;
      Phase 1 portion of the study (completed) will determine the MTD, RP2D, and recommended dosing&#xD;
      regimen. The Phase 2 portion will evaluate activity in selected tumor types. Subjects will&#xD;
      continue to receive their assigned treatment throughout the study until the occurrence of&#xD;
      disease progression, death, or unacceptable treatment-related toxicity, or until the study is&#xD;
      closed by the sponsor.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (Phase 1) - number of subjects with AEs, DLTs, abnormal clinical laboratory values or physical exam results</measure>
    <time_frame>Up to 78 months</time_frame>
    <description>Incidence of dose-limiting toxicities (DLTs) and other adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (Phase 2) - antitumor activity assessed by objective response rate (ORR)</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>Antitumor activity by objective response rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy (Phase 2) - antitumor activity assessed by disease control rate (DCR)</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>Antitumor activity by disease control rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome of concentration-time curve (AUC)</measure>
    <time_frame>First 9 weeks of study treatment</time_frame>
    <description>Assessment of pharmacokinetic parameter area under the concentration-time curve (AUC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome of maximum concentration (Cmax)</measure>
    <time_frame>First 9 weeks of study treatment</time_frame>
    <description>Assessment of pharmacokinetic parameter maximum concentration (Cmax).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome of minimum concentration (Cmin)</measure>
    <time_frame>First 9 weeks of study treatment</time_frame>
    <description>Assessment of pharmacokinetic parameter minimum concentration (Cmin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome of time to maximum concentration (Tmax)</measure>
    <time_frame>First 9 weeks of study treatment</time_frame>
    <description>Assessment of pharmacokinetic parameter time to maximum concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome of samples over time</measure>
    <time_frame>First 9 weeks of study treatment</time_frame>
    <description>Assessment of pharmacokinetic parameter elimination half life (t½).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome of samples over time</measure>
    <time_frame>First 9 weeks of study treatment</time_frame>
    <description>Assessment of pharmacokinetic parameter of other secondary PK parameters of ASTX660 if data permit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic outcome of analysis of ASTX660 metabolites if applicable</measure>
    <time_frame>First 9 weeks of study treatment</time_frame>
    <description>Assessment of pharmacokinetic parameter analysis of ASTX660 metabolites if applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of antitumor response</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>Time from the date of the earliest assessment of complete response or partial response to the date of relapse or death, whichever occurs earlier, or the last efficacy assessment date for subjects without a relapse or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>Number of days from the start of the study treatment to disease progression or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>Number of days from the day the subject received the first study treatment to the date of death, regardless of cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of target (cIAP1) engagement</measure>
    <time_frame>Up to 84 months</time_frame>
    <description>Percentage degradation of cIAP1 protein in PBMCs from baseline, in response to ASTX660 treatment.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Solid Tumors</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1 - Part 1 (completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-escalation stage to identify the MTD and the RP2D, defined as either the MTD or a dose below the MTD that the Data and Safety Review Committee (DSRC) agree shows adequate pharmacological evidence of target engagement and/or clinical activity. Subjects will receive ASTX660 once a day for 7 consecutive days every other week of each 28-day cycle (ie, [7 days on/ 7 days off] ×2; daily dosing on Days 1-7 and 15-21). The starting dose will be escalated stepwise in successive cohorts of 3 to 6 evaluable subjects each (standard 3+3 study design), until the RP2D is determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 - Part 2 (completed)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose-expansion stage to confirm tolerability of ASTX660 at the RP2D using the every-other-week daily dosing regimen. Up to a total of 12 subjects (including the 3 or 6 subjects treated at the RP2D in Part 1) will be treated at the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 - Part 3 (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The purpose of the optional Part 3 is to allow for exploration of an alternative dosing regimen of ASTX660 based on emerging safety, PK, and pharmacodynamic (PD) data from Parts 1 and 2 (using the original every-other-week dosing regimen), with agreement of the DSRC. If Part 3 is conducted, the plan is to enroll up to 18 evaluable subjects in 1 or more cohorts using a standard 3+3 study design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ASTX660 for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) not responsive or relapsed after standard therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ASTX660 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ASTX660 for progressive or relapsed peripheral T-cell lymphoma (PTCL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ASTX660 for relapsed or refractory cutaneous T-cell lymphoma (CTCL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ASTX660 for other tumor types that are characterized by a molecular feature that may confer sensitivity to ASTX660 (eg, oncogenic activation of the NF-κB pathway or documented amplification of the gene loci encoding c-IAP1 or c-IAP2), pending confirmation in writing by the Astex medical monitor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 - Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with ASTX660 for cervical carcinoma not responsive or relapsed after standard therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASTX660</intervention_name>
    <description>described above</description>
    <arm_group_label>Phase 1 - Part 1 (completed)</arm_group_label>
    <arm_group_label>Phase 1 - Part 2 (completed)</arm_group_label>
    <arm_group_label>Phase 1 - Part 3 (optional)</arm_group_label>
    <arm_group_label>Phase 2 - Cohort 1</arm_group_label>
    <arm_group_label>Phase 2 - Cohort 2</arm_group_label>
    <arm_group_label>Phase 2 - Cohort 3</arm_group_label>
    <arm_group_label>Phase 2 - Cohort 4</arm_group_label>
    <arm_group_label>Phase 2 - Cohort 5</arm_group_label>
    <arm_group_label>Phase 2 - Cohort 6</arm_group_label>
    <other_name>Treatment of ASTX660 for advanced solid tumors and lymphomas</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand and comply with the protocol and study procedures, understand the&#xD;
             risks involved in the study, and provide written informed consent before any&#xD;
             study-specific procedure is performed.&#xD;
&#xD;
          2. Men and women 18 years of age or older.&#xD;
&#xD;
          3. Subjects with histologically or cytologically confirmed advanced solid tumors or&#xD;
             lymphoma that is metastatic or unresectable, and for whom standard life-prolonging&#xD;
             measures are not available. Specific tumor types that will be selected for study in&#xD;
             Phase 2 are detailed in the protocol.&#xD;
&#xD;
             a. For Phase 2 Cohort 3, subjects must have histologically confirmed PTCL (local&#xD;
             pathology report) as defined by 2016 World Health Organization (WHO) classification.&#xD;
             The following subtypes are eligible for the study: adult T-cell lymphoma/leukemia,&#xD;
             extranodal natural killer (NK)/T-cell lymphoma nasal type, enteropathy-associated&#xD;
             T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, hepatosplenic&#xD;
             T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, peripheral T-cell&#xD;
             lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, follicular&#xD;
             T-cell lymphoma, nodal peripheral T-cell with T-follicular helper (THF) phenotype, and&#xD;
             anaplastic large-cell lymphoma.&#xD;
&#xD;
          4. For Phase 2 Cohorts 3 and 4, patients must have evidence of documented progressive&#xD;
             disease and must have received at least two prior systemic therapies.&#xD;
&#xD;
               1. Subjects with CD30-positive lymphoma must have received, be ineligible for, or&#xD;
                  intolerant to brentuximab vedotin, provided that brentuximab vedotin is locally&#xD;
                  approved and available.&#xD;
&#xD;
               2. Subjects with mycosis fungoides or Sezary syndrome must have received, be&#xD;
                  ineligible or intolerant to mogamulizumab, provided that mogamulizumab is locally&#xD;
                  approved and available.&#xD;
&#xD;
          5. In the Phase 2 portion of the protocol only, subjects must have measurable disease&#xD;
             according to response criteria appropriate for their type of cancer.&#xD;
&#xD;
             a. For Phase 2 Cohort 3 (PTCL), measurable disease by contrast-enhanced diagnostic CT&#xD;
             (at least 1 nodal lesion &gt;1.5 cm or extranodal lesions &gt;1.0 cm) is required.&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.&#xD;
&#xD;
          7. Acceptable organ function, as evidenced by the following laboratory data:&#xD;
&#xD;
               1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;=2.0 * upper&#xD;
                  limit of normal (ULN).&#xD;
&#xD;
               2. Total serum bilirubin &lt;=1.5 * ULN&#xD;
&#xD;
               3. Absolute neutrophil count (ANC):&#xD;
&#xD;
                    -  Phase 1 and 2 (except Phase 2 subjects with known lymphoma; ie, not&#xD;
                       applicable for Cohorts 3 or 4) &gt;=1500 cells/mm3&#xD;
&#xD;
                    -  Phase 2 subjects with known lymphoma: &gt;=1000 cells/mm3 (&gt;750 cell/mm3 for&#xD;
                       subjects with lymphoma in bone marrow)&#xD;
&#xD;
               4. Platelet count:&#xD;
&#xD;
                    -  Phase 1 and 2 (except Phase 2 subject with known lymphoma; ie, not&#xD;
                       applicable for Cohorts 3 or 4) &gt;=100,000 cells/mm3&#xD;
&#xD;
                    -  Phase 2 subjects with known lymphoma: &gt;= 50,000 cells/mm3; &gt;=25,000&#xD;
                       cells/mm3 for subjects with lymphoma in bone marrow&#xD;
&#xD;
               5. Serum creatinine levels &lt;= 1.5 * ULN, or calculated (by Cockcroft-Gault formula&#xD;
                  or other accepted formula) or measure creatinine clearance &gt;=50 mL/min.&#xD;
&#xD;
               6. Amylase and lipase &lt;=ULN.&#xD;
&#xD;
          8. Women of child-bearing potential (according to recommendations of the Clinical Trial&#xD;
             Facilitation Group [CTFG]; see protocol for details) must not be pregnant or&#xD;
             breastfeeding and must have a negative pregnancy test at screening. Women of&#xD;
             child-bearing potential and men with female partners of child-bearing potential must&#xD;
             agree to practice 2 highly effective contraceptive measures of birth control (as&#xD;
             described in the protocol) and must agree not to become pregnant or father a child&#xD;
             while receiving treatment with study drug and for at least 3 months after completing&#xD;
             treatment. Contraceptive measures which may be considered highly effective comprise&#xD;
             combined hormonal contraception (oral, vaginal, or transdermal) or progestogen-only&#xD;
             hormonal contraception (oral, injectable, implantable) associated with inhibition of&#xD;
             ovulation, intrauterine device, intrauterine hormone-releasing system, bilateral tubal&#xD;
             occlusion, sexual abstinence, and surgically successful vasectomy. Abstinence is&#xD;
             acceptable only if it is consistent with the preferred and usual lifestyle of the&#xD;
             subject. Periodic abstinence (eg, calendar, ovulation, symptothermal, or postovulation&#xD;
             methods) and withdrawal are not acceptable methods of birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hypersensitivity to ASTX660, excipients of the drug product, or other components of&#xD;
             the study treatment regimen.&#xD;
&#xD;
          2. Poor medical risk because of systemic diseases (e.g. active uncontrolled infections)&#xD;
             in addition to the qualifying disease under study.&#xD;
&#xD;
          3. Life-threatening illness, significant organ system dysfunction, or other condition&#xD;
             that, in the investigator's opinion, could compromise subject safety or the integrity&#xD;
             of the study outcomes, or interfere with the absorption or metabolism of ASTX660.&#xD;
&#xD;
          4. History of, or at risk for, cardiac disease, as evidenced by 1 or more of the&#xD;
             following conditions:&#xD;
&#xD;
               1. Abnormal left ventricular ejection fraction (LVEF; &lt;50%) or echocardiogram ECHO&#xD;
                  or multiple gated acquisition scan (MUGA).&#xD;
&#xD;
               2. Congestive cardiac failure of &gt;= Grade 3 severity according to New York Heart&#xD;
                  Association (NYHA) functional classification defined as subjects with marked&#xD;
                  limitation of activity and who are comfortable only at rest.&#xD;
&#xD;
               3. Unstable cardiac disease including angina or hypertension as defined by the need&#xD;
                  for overnight hospital admission within the last 3 months (90 days).&#xD;
&#xD;
               4. History or presence of complete left bundle branch block, heart block, cardiac&#xD;
                  pacemaker or significant arrhythmia.&#xD;
&#xD;
               5. Concurrent treatment with any medical that prolongs QT interval and may induce&#xD;
                  torsades de pointes, and which cannot be discontinued at least 2 weeks before&#xD;
                  treatment with ASTX660. [Applies to Phase 1 only].&#xD;
&#xD;
               6. Personal history of long QTc syndrome or ventricular arrhythmias including&#xD;
                  ventricular bigeminy.&#xD;
&#xD;
               7. Screening 12-lead ECG with measurable QTc interval (according to either&#xD;
                  Fridericia's or Bazett's correction) of &gt;=470 msec).&#xD;
&#xD;
               8. Any other condition that, in the opinion of the investigator, could put the&#xD;
                  subject at increased cardiac risk.&#xD;
&#xD;
          5. Known history of human immunodeficiency virus (HIV) infection, or seropositive results&#xD;
             consistent with active hepatitis B virus (HBV) or active hepatitis C virus (HCV)&#xD;
             infection.&#xD;
&#xD;
          6. Grade 2 or greater neuropathy [Applies to Phase 1]. Grade 3 or greater neuropathy&#xD;
             [Applies to Phase 2].&#xD;
&#xD;
          7. Known brain metastases, unless stable or previously treated.&#xD;
&#xD;
          8. Known significant mental illness or other conditions such as active alcohol or other&#xD;
             substance abuse that, in the opinion of the investigator, predisposes the subject to&#xD;
             high risk of noncompliance with the protocol treatment or assessments.&#xD;
&#xD;
          9. Prior anticancer treatments or therapies within the indicated time window prior to&#xD;
             first dose of study treatment (ASTX660), as follows:&#xD;
&#xD;
               1. Cytotoxic chemotherapy or radiotherapy within 3 weeks prior and any encountered&#xD;
                  treatment-related toxicities (excepting alopecia) not resolved to Grade 1 or less&#xD;
                  [Phase 1] or Grade 2 or less [Phase 2].&#xD;
&#xD;
               2. Skin directed treatments, including topicals and radiation within 2 weeks prior.&#xD;
&#xD;
               3. Monoclonal antibodies within 4 weeks prior and any encountered treatment-related&#xD;
                  toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2 or less [Phase&#xD;
                  2].&#xD;
&#xD;
               4. Small molecules or biologics (investigational or approved) within the longer of 2&#xD;
                  weeks or 5 half-lives prior to study treatment and any encountered&#xD;
                  treatment-related toxicities not resolved to Grade 1 or less [Phase 1] or Grade 2&#xD;
                  or less [Phase 2].&#xD;
&#xD;
               5. At least 6 weeks must have elapsed since CAR-T infusion and subjects must have&#xD;
                  experienced disease progression, and not have residual circulating CAR-T cells in&#xD;
                  peripheral blood (based on local assessment). Any encountered treatment-related&#xD;
                  toxicities must have resolved to Grade ≤1.&#xD;
&#xD;
         10. Concurrent second malignancy currently requiring active therapy, except breast or&#xD;
             prostate cancer stable on or responding to endocrine therapy or superficial bladder&#xD;
             cancer [Phase 2].&#xD;
&#xD;
         11. Known central nervous system (CNS) lymphoma [Phase 2].&#xD;
&#xD;
         12. Patients with a history of allogenic transplant must not have ≥Grade 3&#xD;
             graft-versus-host disease (GVHD) or any clinically significant GVHD requiring systemic&#xD;
             immunosuppression [Phase 2].&#xD;
&#xD;
         13. Systemic corticosteroids &gt;20 mg prednisone equivalent (unless patient has been taking&#xD;
             a continuous dose for &gt;3 weeks prior to study entry and there is documented&#xD;
             radiological progression) [Phase 2]. Stable dose of medium or low potency topical&#xD;
             corticosteroids for at least 3 weeks prior to study entry are permitted [Phase 2].&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Taylor, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Astex Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laksmi Wilson</last_name>
    <phone>+1-925-560-2914</phone>
    <email>Laksmi.Wilson@astx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Purvi Monani</last_name>
    <phone>+1-925-560-2838</phone>
    <email>Purvi.Monani@astx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amitkumar Mehta, MD</last_name>
      <email>amitkumarmehta@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HonorHealth Research Institute</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>852558</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>USC/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Mohrbacher, MD</last_name>
      <email>mohrbach@med.usc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Tuscano</last_name>
      <phone>916-734-5959</phone>
      <email>jtuscano@ucdavis.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Simlow Cancer Hospital at Yale</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francine Foss, MD</last_name>
      <email>francine.foss@yale.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory University winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leonard T. Heffner, Jr., MD</last_name>
      <phone>404-778-5871</phone>
      <email>lheffne@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Robert H. Lurie Comprehensive Cancer Center of Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Pro, M.D.</last_name>
      <phone>312-695-0990</phone>
      <email>barbara.pro@nm.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Wagner-Johnston, MD</last_name>
      <phone>410-955-8839</phone>
      <email>nwagner7@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Jacobsen, MD</last_name>
      <phone>617-582-9086</phone>
      <email>edjacobsen@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryan Wilcox, MD</last_name>
      <phone>734-615-7813</phone>
      <email>rywilcox@med.umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health Systems</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center (DHMC)</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03766</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederick Langisan</last_name>
      <phone>603-650-4628</phone>
      <email>frederick.lansigan@hitchcock.org</email>
    </contact>
    <contact_backup>
      <last_name>Casey O'Quinn</last_name>
      <phone>603-653-9338</phone>
      <email>casey.m.o'quinn@hitchcock.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group - Florham Park Campus/Atlantic Health</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Farber, MD</last_name>
      <phone>973-971-7960</phone>
      <email>charles.farber@atlantichealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Maureen Nowakowski</last_name>
      <phone>973-971-5569</phone>
      <email>maureen.nowakowski@atlantichealth.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco J. Hernandez-Ilizaliturri, MD</last_name>
      <phone>716-845-1359</phone>
      <email>francisco.hernandez@roswellpark.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Diefenbach, MD</last_name>
      <phone>212-731-5670</phone>
      <email>catherine.diefenbach@nyumc.org</email>
    </contact>
    <contact_backup>
      <last_name>Angelica Husni</last_name>
      <phone>646-501-7869</phone>
      <email>angelica.husni@nyulangone.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer K Lue, MD</last_name>
      <phone>212-326-5720</phone>
      <email>jkl2160@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matka Kalac, MD</last_name>
      <phone>212-824-9635</phone>
      <email>matko.kalac@mssm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Keilaa-Demi De La Cruz</last_name>
      <phone>212-824-7337</phone>
      <email>keilaa-demi.delacruz@mssm.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rochester Skin Lymphoma Medical Group</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Poligone, MD, PhD</last_name>
      <phone>585-364-1188</phone>
      <email>bpoligone@roclymphoma.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Health</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rakhee Vaidya, M.B.B.S</last_name>
      <phone>330-272-5972</phone>
      <email>ravaidya@wakehealth.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University and Wexner Medical Center, James Cancer Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basem William, MD</last_name>
      <phone>614-293-3196</phone>
      <email>basem.william@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sami Ibrahimi, MD</last_name>
    </contact>
    <contact_backup>
      <phone>913-940-2351</phone>
      <email>sami-ibrahimi@ouhsc.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Craig Okada, MD</last_name>
      <phone>503-494-8397</phone>
      <email>okadac@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jessica Van Lith</last_name>
      <phone>503-494-9324</phone>
      <email>vanlith@ohsu.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>West Penn Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Lister, MD</last_name>
      <phone>412-578-1605</phone>
      <email>john.lister@ahn.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irl Greenwell, MD</last_name>
      <phone>843-792-4271</phone>
      <email>greenwe@musc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Zic, MD</last_name>
      <phone>615-343-1999</phone>
      <email>john.zic@vanderbilt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Samaniego, MD</last_name>
      <phone>713-563-1509</phone>
      <email>fsamaniego@mdanderson.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CliniCore Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77079</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>START- South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Virgina Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>University of Washington, Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrei R. Shustov, MD</last_name>
      <phone>206-288-6739</phone>
      <email>ashustov@seattlecca.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Universite Catholique de Louvain - Site Godinne</name>
      <address>
        <city>Yvoir</city>
        <state>Namur</state>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien Depaus, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <state>Oost-Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fritz Offner, MD</last_name>
      <phone>+32 9 332 21 32</phone>
      <email>fritz.offner@ugent.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Intitut Jules Boredt</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Maerevoet, MD</last_name>
      <phone>+3225413111</phone>
      <email>marie.maerevoet@bordet.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Shafey, MD</last_name>
      <phone>403-944-8047</phone>
      <email>Mona.Shafey@albertahealthservices.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kerry Savage</last_name>
      <phone>604 877-6000</phone>
      <email>ksavage@bccancer.bc.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Care Manitoba</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3E 0V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roopesh Kansara, MD</last_name>
      <phone>204-237-2006</phone>
      <email>rkansara@cancercare.mb.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Health Athority-Qeii HSC</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary-Margaret Keating, MD</last_name>
      <phone>902-473-7006</phone>
      <email>mary-margaret.keating@nshealth.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Cheung, MD</last_name>
      <phone>416-480-4928</phone>
      <email>matthew.cheung@sunnybrook.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M56 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca Prica, MD</last_name>
      <phone>416-946-2249</phone>
      <email>anca.prica@uhn.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarit Assouline, MD</last_name>
      <phone>514-340-8222</phone>
      <email>sarit.assouline@mcgill.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus (IGR)</name>
      <address>
        <city>Villejuif</city>
        <state>Cedex</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Ribrag, MD</last_name>
      <phone>+33 1 42 11 42 11</phone>
      <email>ribrag@igr.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-Bénite</city>
        <state>Lyon</state>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Bachy, MD</last_name>
      <phone>+33 478862286</phone>
      <email>emmanuel.bachy@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié, Unicancer</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fontanet Bijou, MD</last_name>
      <phone>+33 556 33339</phone>
      <email>f.bijou@bordeaux.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne, Oncologie Médicale</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Peyrade, Prof.</last_name>
      <phone>+33 (0)492 031022</phone>
      <email>frederic.peyrade@nice.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel, Hematology</name>
      <address>
        <city>Rouen</city>
        <zip>1,76-38</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé Tilly, Prof.</last_name>
      <phone>+33 (0)232 082200</phone>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer - Oncopôle, Department d'Hématologie</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc Ysebaert, MD, PhD</last_name>
      <phone>+33(0) 531 156351</phone>
      <email>ysebaert.loic@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CRU de Tours - Hôpital Bretonneau, Hématologie -Thérapy Cellulaire</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel Gyan, Prof.</last_name>
      <phone>+33 (0)247 473712</phone>
      <email>emmanuel.gyan@univ-tours.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem - I. sz. Belgyógyászati Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zsolt Nagy</last_name>
      <phone>+36 1 459 1500</phone>
      <email>nagy.zsolt@med.semmelweis-univ.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Debreceni Egyetem Klinikai Központ</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arpad Illes, MD</last_name>
      <phone>+36 30 945 4801</phone>
      <email>illesarpaddr@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmár-Bereg Megyei Kórházak És Egyetemi Oktatókórház</name>
      <address>
        <city>Nyíregyháza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laszlo Rejto</last_name>
      <phone>+36 7031 6393 0</phone>
      <email>lrejto@med.unideb.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico Sant Orsola-Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pier Luigi Zinzani, MD</last_name>
      <phone>+39 051 2143680</phone>
      <email>pierluigi.zinzani@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandra Tucci, MD</last_name>
      <phone>+39 030-399-5975</phone>
      <email>alessandra.tucci@asst-spedalicivili.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Europeo di Oncologia</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corrado Tarella, MD</last_name>
      <phone>+39 02 57489 538</phone>
      <email>corrado.tarella@ieo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Socio Santaria Territoriale Monza- Osperdale San Gerado</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo G Passerini, MD</last_name>
      <phone>+390392339553</phone>
      <email>carlo.gambacorti@unimib.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Catala d'Oncologia</name>
      <address>
        <city>Girona</city>
        <state>Giona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Gonzalez Barca</last_name>
      <phone>+34 93 2607750</phone>
      <email>e.gonzalez@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>imCORE - Clínica Universidad de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Panizo Santos, MD</last_name>
      <phone>+34 948-296-499</phone>
      <email>cpanizo@unav.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundacion Jimenez Diaz Preview</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul Cordoba Mascunano, MD</last_name>
      <phone>+34915504800</phone>
      <phone_ext>2218</phone_ext>
      <email>raul.cordoba@fjd.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Luis Ortiz Romero, MD</last_name>
      <phone>+34 91 3908302</phone>
      <email>portiz.hdoc@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Leicester NHS Trust</name>
      <address>
        <city>Leicester</city>
        <state>East Midlands</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Dyer, MD</last_name>
      <phone>0044 7950 859 586</phone>
      <email>mjsd1@le.ac.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Southhampton NHS Foundation Trust - Somers Cancer Research</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital, Oxford University Hospital NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Graham Collins, MD</last_name>
      <phone>+441865235886</phone>
      <email>graham.collins@ouh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dima El-Sharkawi, MD</last_name>
      <phone>(44) 20 8642 3116</phone>
      <email>dima.el-sharkawi@rmh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julia Scarisbrick, Prof.</last_name>
      <phone>+44 121 371 5127</phone>
      <email>julia.scarisbrick@uhb.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson Cancer Center and University of Glasgow</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0XL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela McKay, MD</last_name>
      <phone>+44 141 301 7735</phone>
      <email>pam.mckay@ggc.scot.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Townsend, MD</last_name>
      <phone>+44 0203 447 9443</phone>
      <email>william.townsend@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guy's and Saint Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Irene DeFrancesco, MD</last_name>
      <phone>+44 2071 888 4219</phone>
      <email>irene.defrancesco@gstt.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust, Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard Cowan, Prof.</last_name>
      <phone>+44 161 446 3332</phone>
      <email>richard.cowan@christie.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Cowan, MD</last_name>
      <phone>+44 0161 446 3332</phone>
      <email>richard.cowan5@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>July 2, 2015</study_first_submitted>
  <study_first_submitted_qc>July 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2015</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>HNSCC</keyword>
  <keyword>CTCL</keyword>
  <keyword>PTCL</keyword>
  <keyword>DLBCL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

